 NEW YORK , March 22, 2022 PRNewswire -- Synaptogenix, Inc. Nasdaq: SNPX Synaptogenix or the Company, an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon, the Companys President and Chief Scientific Officer, will present a Spotlight Showcase of Synaptogenix under the title Regenerative Therapeutics on Tuesday, March 22nd at 8am ET. Recently reported consolidated results of Synaptogenix Phase 2 clinical trial patients showed significant, persistent improvement of the cognitive psychometric Severe Impairment Battery SIB scores, over baseline, in a placebo-controlled publication on Bryostatin for advanced AD patients Thompson, Tuchman, and Alkon, Journal Alzheimers disease. 